Frost & Sullivan’s Asia-Pacific Pick for Most Innovative New Medical Imaging Product

It is not every day that a medical equipment supplier is recognized for superior innovation and foresight, particularly in an industry that is constantly buzzing with new advancements in technology. For this reason, the distinction of being singled out to receive the 2010 “Medical Imaging Product Innovation of the Year” for the Asia-Pacific region is such an honor for Time Medical.

Frost & Sullivan, a leading global consultancy in the field of market research, is known for honoring only the best and brightest companies in a given field, and in this case they have chosen Time’s HTS technology and their innovative MR imaging systems for their demonstrated excellence in the medical equipment industry. Within the imaging category, Frost & Sullivan’s team of professional analysts conduct extensive market research and interviews with key industry players before deciding upon a winner.

Interestingly, Time Medical is a relatively new player in the world of medical device manufacturing, but its introduction of HTS technology within the MRI market is a pioneering achievement that has shifted the paradigm for magnetic resonance imaging. By introducing a high performance, low-cost solution, Time has set new standards for their competitors and other medical equipment suppliers.

HTS stands for “High Temperature Superconducting” and refers to the RF coil that is used in MR technology. By introducing this new coil to the imaging industry, image quality has been improved by up to 500% and the cost of making an accurate diagnosis has been dramatically reduced. This achievement has made it possible for Time Medical to make diagnosis more accessible to underserved populations in developing countries, specifically in the Asian continent. By shifting the focus of healthcare in these countries from treatment to prevention, medical equipment suppliers like Time Medical hope to use more effective and affordable imaging systems to provide an accurate, low-cost diagnosis.

Twitter This